LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Response to the publication of the Bioeconomy Strategy Progress Report

09/06/2022
PRESS RELEASE
Response to the publication of the Bioeconomy Strategy Progress Report: industrial biotechnology as one of the key drivers towards a more sustainable Europe

Brussels, 9 June 2022 – EuropaBio welcomes the progress report on the 2018 EU Bioeconomy Strategy, marking ten years since the first EU strategy published in 2012. It is crucial to take stock of progress made and identify critical future developments to further advance the implementation of the EU Bioeconomy Strategy.

Beyond assessing the implementation of the 2018 updated Strategy and advances throughout Europe, the progress report frames the increasing importance of the bioeconomy in the current EU policy context. Indeed, when it comes to advancing progress towards EU Green Deal objectives, alternatives to fossil-based products, improved resource efficiency of industrial processes and innovative food and feed are all targets where bioeconomy innovation can deliver.

Claire Skentelbery, Director General of EuropaBio, commented, ‘Industrial biotechnology drives the bioeconomy, using biological systems across sectors and applications to transform products and processes away from petro-chemicals. Europe in particular has a very strong focus on the green transition which means that the role of biotechnology will continue to grow and we will see an increasing number of products on the market that contribute to building a more sustainable European society’.

An innovation-driven circular bioeconomy, with increased sustainability as its end goal, also meets industrial priorities to deliver efficiency, competitiveness and employment. It must increasingly move to large scale biological manufacturing systems across sectors, integrated into the process industry, manufacturing and recycling. In addition to taking stock of the actions set out in the 2018 Bioeconomy Strategy, it is crucial to also consider the bioeconomy in the implementation of other EU Green Deal policies and initiatives.

EuropaBio Response to the publication of the Bioeconomy Strategy Progress Report


Download
2022_06_I_PR_EuropaBio-Response-to-Bioeconomy-Strategy-Progress-ReportDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.